UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 30, 2024

ZimVie Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction of Incorporation)

(Address of Principal Executive Offices)

001-41242 (Commission File Number)

4555 Riverside Drive Palm Beach Gardens, FL

33410

(Zip Code)

87-2007795

(IRS Employer Identification No.)

Registrant's Telephone Number, Including Area Code: (800) 342-5454

Not Applicable (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

П Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

> Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Symbol(s)	on which registered
Common Stock, par value \$0.01 per share	ZIMV	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company \Box

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 🗆

Item 2.02 Results of Operations and Financial Condition.

On October 30, 2024, ZimVie Inc. (the "Company") issued a press release reporting its financial results for the quarter ended September 30, 2024. The press release is attached hereto as Exhibit 99.1 and the information set forth therein is incorporated herein by reference and constitutes a part of this report.

Item 7.01 Regulation FD Disclosure.

On October 30, 2024, the Company also made available a presentation that contains supplemental financial information, including additional full-year 2024 financial guidance. A copy of the presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K and the information set forth therein is incorporated herein by reference.

The information contained in Item 2.02 and Item 7.01 of this report, including Exhibit 99.1 and Exhibit 99.2 hereto, is being furnished and shall not be deemed to be "filed" with the Securities and Exchange Commission for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

EXHIBIT INDEX

Exhibit No. Description

99.1 Press release dated October 30, 2024

99.2 Presentation dated October 30, 2024

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ZimVie Inc.

Date: October 30, 2024

By: /s/ Heather Kidwell Name: Heather Kidwell Title: Senior Vice President, Chief Legal, Compliance and Human Resources Officer and Corporate Secretary



ZimVie Reports Third Quarter 2024 Financial Results

- Third Party Net Sales from Continuing Operations of \$103.2 million
- Net Loss from Continuing Operations of \$(3.0) million; Net Loss margin of (3.0%)
- Adjusted EBITDA^[1] from Continuing Operations of \$13.1 million; Adjusted EBITDA^[1] margin of 12.7%
- GAAP diluted EPS from Continuing Operations of \$(0.11) and adjusted diluted EPS of \$0.12

PALM BEACH GARDENS, Florida, October 30, 2024 (GLOBE NEWSWIRE) – ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended September 30, 2024. Management will host a corresponding conference call today, October 30, 2024, at 4:30 p.m. Eastern Time.

"In the third quarter we saw an improvement to revenue growth in our largest market of North America, achieved manufacturing efficiencies, and saw increased adoption of our digital offerings," said Vafa Jamali, President and Chief Executive Officer. "In addition to our continued focus on driving operational improvement, we made incremental investments in our sales force, R&D initiatives and training programs designed to ensure ZimVie is well positioned for expansion into the future."

Third Quarter 2024 Financial Results: Continuing Operations

Third party net sales for the third quarter of 2024 were \$103.2 million, a decrease of 2.0% on a reported basis and 2.2% in constant currency^[1], versus the third quarter of 2023.

Net loss for the third quarter of 2024 was \$(3.0) million, an improvement of \$7.2 million versus a net loss of \$(10.2) million in the third quarter of 2023. Net loss margin for the third quarter of 2024 was 3.0% of third party net sales, an improvement of 670 basis points versus a net loss margin of 9.7% in the third quarter of 2023.

Adjusted net income^[1] for the third quarter of 2024 was \$3.3 million, an increase of \$2.1 million versus the third quarter of 2023.

Basic and diluted EPS were \$(0.11) and adjusted diluted EPS^[1] was \$0.12 for the third quarter of 2024. Weighted average shares outstanding for both basic and adjusted diluted EPS was 27.6 million.

Adjusted EBITDA^[1] for the third quarter of 2024 was \$13.1 million, or 12.7% of third party net sales, an increase of \$0.9 million or 110 basis points versus the third quarter of 2023.

Updated Full Year 2024 Continuing Operations Financial Guidance:

Projected Year Ending December 31, 2024	Guidance
Net Sales	\$450M to \$455M
Adjusted EBITDA ^[2]	\$ 60M to \$62M
Adjusted EPS ^[2]	\$ 0.57 to \$0.62

- [1] This is a non-GAAP financial measure. Refer to "Note on Non-GAAP Financial Measures" and the reconciliations in this release for further information.
- [2] This is a non-GAAP financial measure for which a reconciliation to the most directly comparable GAAP financial measure is not available without unreasonable efforts. Refer to "Forward-Looking Non-GAAP Financial Measures" in this release, which identifies the information that is unavailable without unreasonable efforts and provides additional information. It is probable that this forward-looking non-GAAP financial measure may be materially different from the corresponding GAAP financial measure.

Conference Call

ZimVie will host a conference call today, October 30, 2024, at 4:30 p.m. ET to discuss its third quarter 2024 financial results. To access the call, please register online at https://investor.zimvie.com/events-presentations/event-calendar. A live and archived audio webcast will also be available on this site.

About ZimVie

ZimVie is a global life sciences leader in the dental market that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. From its headquarters in Palm Beach Gardens, Florida, and additional facilities around the globe, ZimVie works to improve smiles, function, and confidence in daily life by offering comprehensive tooth replacement solutions, including trusted dental implants, biomaterials, and digital workflow solutions. As a worldwide leader in this space, ZimVie is committed to advancing clinical science and technology foundational to restoring daily life. For more information about ZimVie, please visit us at www.ZimVie.com. Follow @ZimVie on Twitter, Facebook, LinkedIn, or Instagram.

Note on Non-GAAP Financial Measures

This press release includes non-GAAP financial measures that differ from financial measures calculated in accordance with U.S. generally accepted accounting principles ("GAAP"). These non-GAAP financial measures may not be comparable to similar measures reported by other companies and should be considered in addition to, and not as a substitute for, or superior to, other measures prepared in accordance with GAAP.

Adjusted EBITDA is a non-GAAP financial measure provided in this release for certain periods and is calculated by excluding certain items from net income (loss) from Continuing Operations on a GAAP basis, as detailed in the reconciliations presented later in this press release. Adjusted EBITDA margin is Adjusted EBITDA divided by third party net sales from Continuing Operations for the applicable period.

Sales change information in this release is presented on a GAAP (reported) basis and on a constant currency basis. Constant currency percentage changes exclude the effects of foreign currency exchange rates. They are calculated by translating current and prior-period sales from Continuing Operations at the same predetermined exchange rate. The translated results are then used to determine year-over-year percentage increases or decreases.

Net income (loss) and diluted earnings (loss) per share in this release are presented on a GAAP (reported) basis and on an adjusted basis. Adjusted net income (loss) and adjusted diluted earnings (loss) per share exclude the effects of certain items, which are detailed in the reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures presented later in this press release.

Reconciliations of these non-GAAP measures to the most directly comparable GAAP financial measures are included in this press release.

Management uses non-GAAP financial measures internally to evaluate the performance of the business. Additionally, management believes these non-GAAP measures provide meaningful incremental information to investors to consider when evaluating the performance of the company. Management believes these measures offer the ability to make period-to-period comparisons that are not impacted by certain items that can cause dramatic changes in reported income, but that do not impact the fundamentals of our operations. The non-GAAP measures enable the evaluation of operating results and trend analysis by allowing a reader to better identify operating trends that may otherwise be masked or distorted by these types of items that are excluded from the non-GAAP measures.

Forward-Looking Non-GAAP Financial Measures

This press release also includes certain forward-looking non-GAAP financial measures for the year ending December 31, 2024. We calculate forwardlooking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. We have not provided quantitative reconciliations of these forward-looking non-GAAP financial measures to the most directly comparable forward-looking GAAP financial measures because the excluded items are not available on a prospective basis without unreasonable efforts. For example, the timing of certain transactions is difficult to predict because management's plans may change. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. It is probable that these forward-looking non-GAAP financial measures may be materially different from the corresponding GAAP financial measures.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including, among others, any statements about our expectations, plans, intentions, strategies, or prospects. We generally use the words "may," "will, "expects," "believes," "anticipates," "plans," "estimates," "projects," "assumes," "guides," "targets," "forecasts," "sees," "seeks," "should," could," "would," "predicts," "potential," "strategy," "future," "opportunity," work toward, "intends," "guidance," "confidence," "positioned," "design," "strive," "continue," "track," "look forward to," "optimistic" and similar expressions to identify forward-looking statements. All statements other than statements of historical or current fact are or may build work to be forward believe to the totage to be to the totage to be totage. be deemed to be forward-looking statements. Such statements are based upon the current beliefs, expectations, and assumptions of management and are subject to significant risks, uncertainties, and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements. These risks, uncertainties and changes in circumstances include, but are not limited to: dependence on new product development, technological advances and innovation; shifts in the product category or regional sales mix of our products and services; supply and prices of raw materials and products; pricing pressures from competitors, customers, dental practices and insurance providers; changes in customer demand for our products and services caused by demographic changes or other factors; challenges relating to changes in and compliance with governmental laws and regulations affecting our U.S. and international businesses, including regulations of the U.S. Food and Drug Administration and foreign government regulators, such as more stringent requirements for regulatory clearance of products; competition; the impact of healthcare reform measures; reductions in reimbursement levels by third-party payors; cost containment efforts sponsored by government agencies, legislative bodies, the private sector and healthcare group purchasing organizations, including the volume-based procurement process in China; control of costs and expenses; dependence on a limited number of suppliers for key raw materials and outsourced activities; the ability to obtain and maintain adequate intellectual property protection; breaches or failures of our information technology systems or products, including by cyberattack, unauthorized access or theft; the ability to retain the independent agents and distributors who market our products; our ability to attract, retain and develop the highly skilled employees we need to support our business; the effect of mergers and acquisitions on our relationships with customers, suppliers and lenders and on our operating results and businesses generally; the ability to form and implement alliances; changes in tax obligations arising from tax reform measures, including European Union rules on state aid, or examinations by tax authorities; product liability, intellectual property and commercial litigation losses; changes in general industry and market conditions, including domestic and international growth rates; changes in general domestic and international economic conditions, including inflation and interest rate and currency exchange rate fluctuations; the effects of global pandemics and other adverse public health developments on the global economy, our business and operations and the business and operations of our suppliers and customers, including the deferral of elective procedures and our ability to collect accounts receivable; and the impact of the ongoing financial and political uncertainty on countries in the Euro zone on the ability to collect accounts receivable in affected countries. You are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. Forward-looking statements speak only as of the date they are made, and we expressly disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media Contact Information:

ZimVie

Grace Flowers • <u>Grace.Flowers@ZimVie.com</u> (561) 319-6130

Investor Contact Information:

Gilmartin Group LLC

Marissa Bych • Marissa@gilmartinir.com

ZIMVIE INC. CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (UNAUDITED) (in thousands, except per share data)

		For the Three Months Ended September 30,		ne Months tember 30,
N - 0 1	2024	2023	2024	2023
Net Sales	¢ 102 222	6 105 211	e 220 220	0 244 121
Third party, net	\$ 103,222	\$ 105,311	\$ 338,228	\$ 344,131
Related party, net				236
Total Net Sales	103,222	105,311	338,228	344,367
Cost of products sold, excluding intangible asset amortization	(35,820)	(36,907)	(123,596)	(124,246)
Related party cost of products sold, excluding intangible asset amortization				(231)
Intangible asset amortization	(6,037)	(6,778)	(18,059)	(20,378)
Research and development	(6,926)	(5,677)	(20,285)	(19,365)
Selling, general and administrative	(57,313)	(56,505)	(180,024)	(186,054)
Restructuring and other cost reduction initiatives	(687)	(1,391)	(3,664)	(3,929)
Acquisition, integration, divestiture and related	(1,276)	(1,936)	(6,934)	(4,647)
Operating expenses	(108,059)	(109,194)	(352,562)	(358,850)
Operating Loss	(4,837)	(3,883)	(14,334)	(14,483)
Other income (expense), net	3,462	(990)	6,161	(1,189)
Interest income	2,466	569	4,938	1,929
Interest expense	(4,827)	(5,553)	(14,766)	(17,187)
Loss from continuing operations before income taxes	(3,736)	(9,857)	(18,001)	(30,930)
Benefit (provision) for income taxes from continuing operations	688	(325)	(6,161)	(1,555)
Net Loss from Continuing Operations of ZimVie Inc.	(3,048)	(10,182)	(24,162)	(32,485)
Earnings (loss) from discontinued operations, net of tax	764	5,093	10,103	(25,945)
Net Loss of ZimVie Inc.	\$ (2,284)	\$ (5,089)	\$ (14,059)	\$ (58,430)
Basic (Loss) Earnings Per Common Share:				
Continuing operations	\$ (0.11)	\$ (0.38)	\$ (0.88)	\$ (1.23)
Discontinued operations	0.03	0.19	0.37	(0.98)
Net Loss	\$ (0.08)	\$ (0.19)	\$ (0.51)	\$ (2.21)
Diluted (Loss) Earnings Per Common Share				
Continuing operations	\$ (0.11)	\$ (0.38)	\$ (0.88)	\$ (1.23)
Discontinued operations	0.03	0.19	0.37	(0.98)
Net Loss	\$ (0.08)	\$ (0.19)	\$ (0.51)	\$ (2.21)

ZIMVIE INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (in thousands, except per share data)

Accounts receivable, less allowance for credit losses of \$2,392 66 Inventories 77 Prepaid expenses and other current assets 22 Current assets of discontinued operations 21 Total Current Assets 26 Property, plant and equipment, net of accumulated depreciation 26 of \$131,717 and \$126,624, respectively 49 Goodwill 26 Intangible assets, net 94 Note receivable 66 Other assets 3 Noncurrent assets of discontinued operations 11 Total Assets \$ 783 LIABILITIES AND EQUITY \$ Current Liabilities: \$ 783 Accounts payable \$ 21 Income taxes payable \$ 22 Income taxes payable 5 Other current Liabilities 53 Current liabilities 53 Other current Liabilities 54 Other current liabilities </th <th>2024 Decc 5,808 \$ 9,581 7,087 4,162 5,036 5,674 - 0,614 2,767 3,251 3,072</th> <th>71,511 65,168 79,600 23,825 242,773 482,877 54,167 262,111 114,354</th>	2024 Decc 5,808 \$ 9,581 7,087 4,162 5,036 5,674 - 0,614 2,767 3,251 3,072	71,511 65,168 79,600 23,825 242,773 482,877 54,167 262,111 114,354
Current Assets: \$ 66 Accounts receivable, less allowance for credit losses of \$2,392 66 Accounts receivable, less allowance for credit losses of \$2,392 66 Inventories 77 Prepaid expenses and other current assets 22 Current Assets 226 Total Current Assets 266 Property, plant and equipment, net of accumulated depreciation 266 Other assets of discontinued operations 266 Intangible assets, net 266 Other assets 266 Other assets 266 Other assets 266 Other assets of discontinued operations 266 Other assets 33 Noncurrent assets of discontinued operations 112 Total Assets \$ 78 LABILITIES AND EQUITY 20 Current Liabilities: 33 Accounts payable 5 Other current liabilities 53 Current Liabilities 133 Deferred income taxes 44 Total Current Liabilities 45 Other long-term liabilities 45 <th>2,581 7,087 4,162 3,036 5,674 2,6614 2,767 3,251</th> <th>65,168 79,600 23,825 242,773 482,877 54,167 262,111</th>	2,581 7,087 4,162 3,036 5,674 2,6614 2,767 3,251	65,168 79,600 23,825 242,773 482,877 54,167 262,111
Cash and cash equivalents \$ 66 Accounts receivable, less allowance for credit losses of \$2,392 66 Inventories 77 Prepaid expenses and other current assets 22 Current assets of discontinued operations 224 Total Current Assets 266 Property, plant and equipment, net of accumulated depreciation 66 of \$131,717 and \$126,624, respectively 44 Goodwill 266 Intangible assets, net 99 Note receivable 66 Other assets 3 Noncurrent assets of discontinued operations 11 Total Assets 5 78 LIABILITIES AND EQUITY 12 Current Liabilities: 5 78 Accounts payable 5 2 Other current liabilities 55 55 Current Liabilities 55 51 Other current Liabilities 51 52 Accounts payable 5 2 52 Income taxes payable 51 51 Other current liabilities 52 51 O	2,581 7,087 4,162 3,036 5,674 2,6614 2,767 3,251	65,168 79,600 23,825 242,773 482,877 54,167 262,111
Accounts receivable, less allowance for credit losses of \$2,392 66 Inventories 77 Prepaid expenses and other current assets 22 Current assets of discontinued operations 24 Total Current Assets 266 Property, plant and equipment, net of accumulated depreciation 266 Ordwill 266 Intangible assets, net 94 Note receivable 66 Other assets 33 Noncurrent assets of discontinued operations 11 Total Assets 5 LIABILITIES AND EQUITY 5 Current Liabilities: 3 Accounts payable 5 Other current Liabilities 5 Current Liabilities 34 Total Current Liabilities 34 Other current Liabilities 54 Other current Liabilities 54 Other current liabilities 54 Other current liabilities 34 Other current liabilities 54 Other current liabilities 54 Other current liabilities 54 Other current liabilities <td< th=""><th>2,581 7,087 4,162 3,036 5,674 2,6614 2,767 3,251</th><th>65,168 79,600 23,825 242,773 482,877 54,167 262,111</th></td<>	2,581 7,087 4,162 3,036 5,674 2,6614 2,767 3,251	65,168 79,600 23,825 242,773 482,877 54,167 262,111
and \$3,222 respectively 66 Inventories 77 Prepaid expenses and other current assets 22 Current Assets of discontinued operations 22 Total Current Assets 26 Property, plant and equipment, net of accumulated depreciation 26 Intangible assets, net 26 Note receivable 26 Other assets 31 Noncurrent assets of discontinued operations 11 Total Assets 5 ILABILITIES AND EQUITY 5 Current Liabilities 21 Accounts payable 5 Other current liabilities 31 Other current liabilities 32 Urrent liabilities 31 Other current liabilities 32 Other current liabilities 33 Other current liabilities 33 Other current liabilities 33 Other current liabilities 34 Total Current liabilities 34 Other current liabilities 34 Other current liabilities 34 <td< td=""><td>7,087 4,162 3,036 5,674 0,614 2,767 3,251</td><td>79,600 23,825 242,773 482,877 54,167 262,111</td></td<>	7,087 4,162 3,036 5,674 0,614 2,767 3,251	79,600 23,825 242,773 482,877 54,167 262,111
Inventories 7 Prepaid expenses and other current assets 2 Current assets of discontinued operations 21 Total Current Assets 26 Property, plant and equipment, net of accumulated depreciation 26 of \$131,717 and \$126,624, respectively 44 Goodwill 26 Intangible assets, net 29 Note receivable 66 Other assets 3 Noncurrent assets of discontinued operations 11 Total Assets \$ 78 LIABILITIES AND EQUITY 21 Current Liabilities: 3 Accounts payable 5 Other current liabilities 53 Current Liabilities 13 Deferred income taxes 44 Total Current Liabilities 13 Deferred income taxes 21 Other long-term liabilities 32 Other long-term liabilities 32 Other long-term liabilities 32 Non-current portion of debt 220 Non-current liabilities of discontinued operations 32 Non-current liabilities of discontinued	7,087 4,162 3,036 5,674 0,614 2,767 3,251	79,600 23,825 242,773 482,877 54,167 262,111
Prepaid expenses and other current assets 22 Current assets of discontinued operations 22 Total Current Assets 26 Property, plant and equipment, net of accumulated depreciation 44 Goodwill 266 Intangible assets, net 99 Note receivable 66 Other assets 33 Noncurrent assets of discontinued operations 11 Total Assets \$ 78 LIABLITIES AND EQUITY 44 Current Liabilities: 5 Accounts payable \$ 22 Income taxes payable 5 Other current liabilities 55 Current Liabilities 55 Current Liabilities 134 Total Current Liabilities 134 Deferred income taxes 9 Uease liability 9 Other long-term liabilities 26 Other long-term liabilities 20 Noncurrent liabilities of discontinued operations 21 Icome taxes 22 Noncurrent liabilities 22 Noncurrent liabilities 22 <t< td=""><td>4,162 3,036 5,674 9,614 2,767 3,251</td><td>23,825 242,773 482,877 54,167 262,111</td></t<>	4,162 3,036 5,674 9,614 2,767 3,251	23,825 242,773 482,877 54,167 262,111
Current assets of discontinued operations 24 Total Current Assets 263 Property, plant and equipment, net of accumulated depreciation 44 Goodwill 266 Intangible assets, net 94 Note receivable 66 Other assets 3 Noncurrent assets of discontinued operations 11 Total Assets \$ 783 LIABILITIES AND EQUITY 5 Current Liabilities: 4 Accounts payable 5 Other current liabilities 54 Other reurent Liabilities 54 Other reurent Liabilities 54 Other reurent Liabilities 54 Other current liabilities 54 Other current liabilities 54 Other current liabilities 54	3,036 5,674 9,614 2,767 3,251	242,773 482,877 54,167 262,111
Total Current Assets 265 Property, plant and equipment, net of accumulated depreciation 44 of \$131,717 and \$126,624, respectively 44 Goodwill 266 Intangible assets, net 99 Note receivable 66 Other assets 3 Noncurrent assets of discontinued operations 11 Total Assets \$ 783 LIABILITIES AND EQUITY \$ Current Liabilities: \$ Accounts payable \$ Other current liabilities 513 Other current liabilities 53 Current liabilities 134 Total Current Liabilities 134 Other current liabilities 134 Other current liabilities 134 Other current liabilities 134 Deferred income taxes 94 Other long-term liabilities 220 Noncurrent portion of debt 220 Noncurrent liabilities of discontinued operations 370 Total Liabilities 370	2,614 2,767 3,251	482,877 54,167 262,111
Property, plant and equipment, net of accumulated depreciation 4 of \$131,717 and \$126,624, respectively 44 Goodwill 26 Intangible assets, net 99 Note receivable 66 Other assets 3 Noncurrent assets of discontinued operations 12 Total Assets \$ 78 LIABILITIES AND EQUITY 5 22 Income taxes payable \$ 22 Income taxes payable 53 21 Other current liabilities 53 53 Current Liabilities 53 54 Other current liabilities 13 54 Other long-term liabilities 54 54 Noncurrent liabilities of discontinued operations 54 54 Noncurre	9,614 2,767 3,251	54,167 262,111
of \$131,717 and \$126,624, respectively 44 Goodwill 266 Intangible assets, net 94 Note receivable 66 Other assets 3 Noncurrent assets of discontinued operations 11 Total Assets \$ 78 LIABILITIES AND EQUITY 5 Current Liabilities: \$ 22 Income taxes payable 5 Other current liabilities 51 Current Liabilities 51 Current Liabilities 51 Current Liabilities 51 Other current liabilities 51 Current Liabilities 51 Other current liabilities 51 Other current liabilities 51 Other current liabilities 52 Income taxes 130 Deferred income taxes 130 Deferred income taxes 20 Non-current liabilities 20 Non-current portion of debt 22 Noncurrent liabilities of discontinued operations 21 Noncurrent liabilities of discontinued operations 21 Noncurrent liabilities of discontinued operations 21	2,767 3,251	262,111
Goodwill 260 Intangible assets, net 99 Note receivable 60 Other assets 33 Noncurrent assets of discontinued operations 11 Total Assets 5 LIABILITIES AND EQUITY 5 Current Liabilities: 5 Accounts payable 5 Other current liabilities 55 Current liabilities 55 Current liabilities 55 Current liabilities 130 Deferred income taxes 130 Deferred income taxes 9 Uease liability 9 Other long-term liabilities 9 Non-current liabilities of discontinued operations 22 Non-current liabilities 9 Other long-term liabilities 9 Other of discontinued operations 9 Total Liabilities of discontinued operations 9 Total Liabilities of discontinued operations 9 Noncurrent liabilities of discontinued operations 9 Noncurrent liabilities of discontinued operations 9 Noncurrent liabilities of discontinued operations 9	2,767 3,251	262,111
Intangible assets, net 94 Note receivable 66 Other assets 3 Noncurrent assets of discontinued operations 11 Total Assets \$ 783 LIABILITIES AND EQUITY \$ Current Liabilities: 4 Accounts payable \$ Other current liabilities 53 Current liabilities 54 Other current liabilities 54 Deferred income taxes 134 Total Current Liabilities 134 Other liabilities 134 Other liabilities 54 Other of discontinued operations 44 Total Current Liabilities 134 Deferred income taxes 9 Ucher liabilities 24 Non-current protion of debt 220 Noncurrent liabilities of discontinued operations 24 Total Liabilities of discontinued operations 24	3,251	
Note receivable 66 Other assets 3 Noncurrent assets of discontinued operations 12 Total Assets \$ 78 LLABILITIES AND EQUITY 2 Current Liabilities: 3 Accounts payable \$ 22 Income taxes payable 53 Other current liabilities 53 Current Liabilities 13 Deferred income taxes 12 Lease liability 9 Other long-term liabilities 20 Non-current portion of debt 20 Non-current liabilities of discontinued operations 20 Total Liabilities 370		114,354
Other assets 3 Noncurrent assets of discontinued operations 11 Total Assets \$ ItaBILITIES AND EQUITY 5 Current Liabilities: \$ Accounts payable \$ Current liabilities \$ Other current liabilities \$ Other current Liabilities \$ Current Liabilities \$ Other current Liabilities \$ Other long-term liabilities \$ Lease liability \$ Other long-term liabilities \$ Non-current portion of debt \$ Non-current liabilities of discontinued operations \$ Total Liabilities \$	3,072	
Noncurrent assets of discontinued operations 11 Total Assets \$ IABLITIES AND EQUITY 78 Current Liabilities: 5 Accounts payable \$ Other current liabilities 55 Current liabilities 55 Current Liabilities 55 Current Liabilities 51 Other current liabilities 130 Deferred income taxes 130 Deferred income taxes 9 Other long-term liabilities 9 Non-current portion of debt 20 Noncurrent liabilities of discontinued operations 9 Total Liabilities of discontinued operations 370		
Total Assets \$ 783 LIABILITIES AND EQUITY 783 Current Liabilities: 783 Accounts payable \$ 22 Income taxes payable 53 Other current liabilities 53 Current liabilities 54 Total Current Liabilities 134 Deferred income taxes 134 Deferred income taxes 9 Other long-term liabilities 9 Non-current portion of debt 220 Noncurrent liabilities of discontinued operations 376	1,271	26,747
LIABILITIES AND EQUITY Current Liabilities: Accounts payable Accounts payable Current liabilities Current	2,299	265,089
Current Liabilities: \$ 2' Accounts payable \$ 2' Income taxes payable \$ 2' Other current liabilities \$ 4' Total Current Liabilities 13' 13' Deferred income taxes \$ 2' Lease liability \$ 9' Other long-term liabilities \$ 2' Non-current portion of debt \$ 22' Non-current liabilities of discontinued operations \$ 37' Total Liabilities \$ 37'	2,948 \$	1,205,345
Accounts payable \$ 2' Income taxes payable 5' Other current liabilities 5' Current liabilities of discontinued operations 4' Total Current Liabilities 13' Deferred income taxes 1' Lease liability 0' Other long-term liabilities 2' Non-current portion of debt 2' Non-current liabilities of discontinued operations 3'		
Income taxes payable 2 Other current liabilities 55 Current liabilities 44 Total Current Liabilities 130 Deferred income taxes 130 Lease liability 9 Other long-term liabilities 220 Non-current portion of debt 220 Non-current liabilities of discontinued operations 370		
Other current liabilities 55 Current liabilities 44 Total Current Liabilities 134 Deferred income taxes 135 Lease liability 9 Other long-term liabilities 20 Non-current portion of debt 220 Non-current liabilities of discontinued operations 370 Total Liabilities 370	7,403 \$	27,785
Current liabilities of discontinued operations 44 Total Current Liabilities 130 Deferred income taxes 9 Lease liability 9 Other long-term liabilities 9 Non-current portion of debt 220 Noncurrent liabilities of discontinued operations 370	2,440	2,863
Total Current Liabilities 13 Deferred income taxes 13 Lease liability 0 Other long-term liabilities 220 Non-current portion of debt 220 Noncurrent liabilities of discontinued operations 370	3,363	67,108
Deferred income taxes 2 Lease liability 0 Other long-term liabilities 2 Non-current portion of debt 220 Noncurrent liabilities of discontinued operations 370 Total Liabilities 370	3,432	75,858
Lease liability 9 Other long-term liabilities 0 Non-current portion of debt 220 Noncurrent liabilities of discontinued operations 370 Total Liabilities 3370	5,638	173,614
Other long-term liabilities 220 Non-current portion of debt 220 Noncurrent liabilities of discontinued operations 370	276	265
Non-current portion of debt 220 Noncurrent liabilities of discontinued operations 370 Total Liabilities 370	9,477	9,080
Noncurrent liabilities of discontinued operations Total Liabilities 370	9,269	9,055
Total Liabilities 370),281	508,797
	369	95,041
	5,310	795,852
Commitments and Contingencies		
Stockholders' Equity:		
Common stock, \$0.01 par value, 150,000 shares authorized Shares, issued and outstanding, of		
27,587 and 27.076, respectively		271
Preferred stock, \$0.01 par value, 15,000 shares authorized, 0 shares issued and outstanding	276	_
	276	922,996
Accumulated deficit (45-	276	(440,814)
Accumulated other comprehensive loss (72	_	(70.0.00)
	3,735	(72,960)
Total Liabilities and Stockholders' Equity \$ 78.		(72,960) 409,493

ZIMVIE INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (in thousands)

	 the Nine Months Er 2024	2023	
Cash flows (used in) provided by operating activities:			
Net loss of ZimVie Inc.	\$ (14,059)	\$	(58,430
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:			
Depreciation and amortization	25,697		95,088
Share-based compensation	12,473		16,129
Deferred income tax provision	(4,201)		(11,967
Loss on disposal of fixed assets	418		2,411
Other non-cash items	2,818		2,762
Gain on sale of spine disposal group	(22,427)		—
Changes in operating assets and liabilities:			
Income taxes	2,548		(34,061
Accounts receivable	(5,742)		13,019
Related party receivables	_		8,483
Inventories	7,139		18,246
Prepaid expenses and other current assets	(2,447)		4,187
Accounts payable and accrued liabilities	(6,314)		(18,216
Related party payable	—		(13,177
Other assets and liabilities	(3,179)		(8,780
Net cash (used in) provided by operating activities	 (7,276)		15,694
ash flows provided by (used in) investing activities:			
Additions to instruments	(1,316)		(4,341
Additions to other property, plant and equipment	(2,677)		(5,340
Proceeds from sale of spine disposal group, net of cash disposed	291,123		_
Other investing activities	(1,961)		(2,762
Net cash provided by (used in) investing activities	285,169		(12,443
Cash flows used in financing activities:	 <u> </u>		
Proceeds from debt	_		4,760
Payments on debt	(290,000)		(22,291
Business combination contingent consideration payments	(3,712)		_
Payments related to tax withholding for share-based compensation	(1,729)		(419
Proceeds from stock plan activity	_		1,167
Net cash used in financing activities	 (295,441)		(16,783
Effect of exchange rates on cash and cash equivalents	 (2,124)		(620
Decrease in cash and cash equivalents	 (19,672)		(14,152
Cash and cash equivalents, beginning of year	87,768		89,601
Cash and cash equivalents, end of period	\$ 68,096	\$	75,449
	 	-	,

 $\label{eq:presentation} Presentation\ includes\ cash\ of\ both\ continuing\ and\ discontinued\ operations$

RECONCILIATION OF CONSTANT CURRENCY NET SALES Continuing Operations (\$ in thousands)

		For the Three Months Ended September 30,			Constant Currency %	
	2024	2023	Change (%)	Exchange Impact	Change	
United States	\$ 65,350	\$ 65,003	0.5%	0.0%	0.5%	
International	37,872	40,308	(6.0%)	0.6%	(6.6%)	
Total Dental Third Party Sales	103,222	105,311	(2.0%)	0.2%	(2.2%)	
Related Party Net Sales		_	0.0%	0.0%	0.0%	
Total Dental Net Sales	\$103,222	\$105,311	(2.0%)	0.2%	(2.2%)	

	For the Ni Ended Sep			Foreign Exchange	Constant Currency %
	2024	2023	Change (%)	Impact	Change
United States	\$202,414	\$204,173	(0.9%)	0.0%	(0.9%)
International	135,814	139,958	(3.0%)	(1.0%)	(2.0%)
Total Dental Third Party Sales	338,228	344,131	(1.7%)	(0.4%)	(1.3%)
Related Party Net Sales		236	(100.0%)	0.0%	(100.0%)
Total Dental Net Sales	\$338,228	\$344,367	(1.8%)	(0.4%)	(1.4%)

RECONCILIATION OF ADJUSTED NET INCOME AND DILUTED EPS Continuing Operations (in thousands, except per share data)

	For the Three Months Ended September 30, 2024							
	Net Sales	pro e: in	Cost of ducts sold, xcluding atangible asset ortization	Operating expenses, excluding cost of products sold	Operating (Loss) Income	Net (Loss) Income	Dih	ited EPS
Reported	\$103,222	\$	(35,820)	\$(72,239)	\$ (4,837)	\$(3,048)	\$	(0.11)
Restructuring and other cost reduction initiatives [1]	_		_	687	687	687		0.02
Acquisition, integration, divestiture and related ^[2]	—		—	1,276	1,276	1,276		0.05
European union medical device regulation [3]	—		_	406	406	406		0.01
Other charges [4]	_		287	_	287	287		0.01
Intangible asset amortization	—		_	6,037	6,037	6,037		0.22
Share-based compensation modification [5]	—		—	(521)	(521)	(521)		(0.02)
Tax effect of above adjustments & other [6]			—	_	_	(1,841)		(0.06)
Adjusted	\$103,222	\$	(35,533)	\$(64,354)	\$ 3,335	\$ 3,283	\$	0.12

		For the TI	hree Months En	ded September	30, 2023	
	Net Sales	Cost of products sold, excluding intangible asset amortization	Operating expenses, excluding cost of products sold	Operating (Loss) Income	Net (Loss) Income	Diluted EPS
Reported	\$105,311	\$ (36,907)	\$(72,287)	\$ (3,883)	\$(10,182)	\$ (0.38)
Restructuring and other cost reduction initiatives [1]	—	—	1,391	1,391	1,391	0.05
Acquisition, integration, divestiture and related [2]	—	—	1,936	1,936	1,936	0.07
European union medical device regulation [3]	_	_	295	295	295	0.01
Intangible asset amortization	_	_	6,778	6,778	6,778	0.26
Other charges [4]	_	293	_	293	293	0.01
Spin-related share-based compensation expense [7]	—	_	800	800	800	0.03
Tax effect of above adjustments & other [6]					(100)	
Adjusted	\$105,311	\$ (36,614)	\$(61,087)	\$ 7,610	\$ 1,211	\$ 0.05

 Restructuring activities to better position the organization and the expenses incurred were primarily related to severance and professional fees.
 Acquisition, integration, divestiture and related expenses for the three months ended September 30, 2024 include professional services fees (\$1.9 million) and stranded costs (\$0.4 million) related to sale of the spine segment, partially offset by a fair value adjustment benefit of the seller note related to the sale of the spine segment (\$1.2 million). Acquisition, integration, divestiture and related expenses for the three months ended September 30, 2023 include professional services fees (\$1.6 million) and rebranding costs (\$0.3 million) related to the separation from our former parent.

[3] Expenses incurred for initial compliance with the European Union ("EU") Medical Device Regulation ("MDR") for previously-approved products. Inventory write-offs resulting from restructuring activities and property, plant, and equipment step-up amortization from prior acquisitions.

[4] [5]

Net impact to share-based compensation expense of converting outstanding restricted stock units ("RSUs") with performance-based metrics based on the consolidated results of the spine and dental segments into time-based RSUs following the sale of the spine segment.

[6] Reflects the tax effect of the adjustments from reported to adjusted, as well as an adjustment for management's expectation of ZimVie's statutory tax rate based on current tax law and adjusted pre-tax income.
[7] Spin-related share-based compensation expense from grants provided due to the successful separation from Zimmer Biomet.

RECONCILIATION OF ADJUSTED EBITDA: Continuing Operations (\$ in thousands)

	Ended Sept	Ended September 30, E		tember 30,
Net Sales	2024	2023	2024	2023
Total Third Party Sales	\$103,222	\$105,311	\$338,228	\$344,131
Related Party Sales	\$103,222	\$105,511	\$336,226	236
	<u> </u>			
Total Net Sales	\$103,222	\$105,311	\$338,228	\$344,367
Net Loss	\$ (3,048)	\$(10,182)	\$ (24,162)	\$ (32,485)
Interest expense, net	2,361	4,984	9,828	15,258
Income tax (benefit) provision	(688)	325	6,161	1,555
Depreciation and amortization	8,490	8,415	25,383	26,057
EBITDA	7,115	3,542	17,210	10,385
Share-based compensation	3,323	4,741	11,761	14,159
Restructuring and other cost reduction initiatives [1]	687	1,391	3,664	3,929
Acquisition, integration, divestiture and related [2]	1,276	1,936	6,934	4,647
Related party gain	_	_	_	(5)
European Union medical device regulation [3]	406	295	1,118	2,227
Other charges [4]	287	293	860	864
Adjusted EBITDA	\$ 13,094	\$ 12,198	\$ 41,547	\$ 36,206
Net Loss Margin ^[5]	-3.0%	-9.7%	-7.1%	-9.4%
Adjusted EBITDA Margin [6]	12.7%	11.6%	12.3%	10.5%

[1] Restructuring activities to better position our organization for future success based on the current business environment and sale of the spine business. Acquisition, integration, divestiture and related expenses for the three and nine months ended September 30, 2024 include professional services

[2] fees (\$1.9 million and \$5.8 million, respectively) and stranded costs (\$0.4 million and \$0.9 million, respectively) related to sale of the spine segment, partially offset by fair value adjustment benefit of the seller note related to the sale of the spine segment (\$1.2 million and \$0, respectively). Acquisition, integration, divestiture and related expenses for the tree and nine months ended September 30, 2023 include professional services fees (\$1.6 million and \$3.2 million, respectively), rebranding costs related to the separation from our former parent (\$0.3 million and \$0.5 million, respectively) and technology costs (\$0 and \$0.7 million, respectively) incurred to prepare for and complete the separation from our former parent. Expenses incurred for initial compliance with the EU MDR for previously-approved products.

[3]

[4] Inventory write-offs resulting from restructuring activities and property, plant, and equipment step-up amortization from prior acquisitions.

[5] [6] Net Loss Margin is calculated as Net Loss divided by third party net sales for the applicable period. Adjusted EBITDA Margin is Adjusted EBITDA divided by third party net sales for the applicable period.

RECONCILIATION OF COST OF PRODUCTS SOLD (excluding intangible asset amortization), R&D and SG&A: Continuing Operations (\$ in thousands)

	Three M Ended Sep	tember 30,	Percentage Party Net	Sales	Nine N Ended Sep	tember 30,	Percentage Party Net	Sales
	2024	2023	2024	2023	2024	2023	2024	2023
Cost of products sold, excluding intangible asset	e (25.020)	e (2(007)	(24.70/)	(25.00/)	¢(122.50C)	6(124.240)	(26.50/)	(2(10/)
amortization	\$(35,820)	\$(36,907)	(34.7%)	(35.0%)	\$(123,596)	\$(124,246)	(36.5%)	(36.1%)
Other charges [1]	287	293	0.3%	0.2%	860	864	0.2%	0.2%
Adjusted cost of products sold, excluding intangible								
asset amortization	\$(35,533)	\$(36,614)	(34.4%)	(34.8%)	\$(122,736)	\$(123,382)	(36.3%)	(35.9%)
	2024	2023	2024	2023	2024	2023	2024	2023
Research and development	\$ (6,926)	\$ (5,677)	(6.7%)	(5.4%)	\$ (20,285)	\$ (19,365)	(6.0%)	(5.6%)
European union medical device regulation [2]	406	295	0.3%	0.3%	1,118	2,227	0.3%	0.6%
Share-based compensation modification [3]	(45)	—	0.0%	0.0%	(45)	_	0.0%	0.0%
Spin-related share-based compensation expense [4]	—	80	0.0%	0.1%	_	240	0.0%	0.1%
Adjusted research and development	\$ (6,565)	\$ (5,302)	(6.4%)	(5.0%)	\$ (19,212)	\$ (16,898)	(5.7%)	(4.9%)
	2024	2023	2024	2023	2024	2023	2024	2023
Selling, general and administrative	\$(57,313)	\$(56,505)	(55.5%)	(53.7%)	\$(180,024)	\$(186,054)	(53.2%)	(54.1%)
Share-based compensation modification [3]	(476)	_	(0.5%)	0.0%	(476)	_	(0.2%)	0.0%
Spin-related share-based compensation expense [4]	_	720	0.0%	0.7%	—	2,160	0.0%	0.7%
Adjusted selling, general and administrative	\$(57,789)	\$(55,785)	(56.0%)	(53.0%)	\$(180,500)	\$(183,894)	(53.4%)	(53.4%)

[1]

Inventory write-offs resulting from restructuring activities and property, plant, and equipment step-up amortization from prior acquisitions. Expenses incurred for initial compliance with the EU MDR for previously-approved products. Net impact to share-based compensation expense of converting outstanding RSUs with performance-based metrics based on the consolidated results of the spine and dental segments to time-based RSUs following the sale of the spine segment. Spin-related share-based compensation expense from grants provided due to the successful separation from Zimmer Biomet. [2] [3]

[4]



A Global Dental Leader October 2024

Forward-Looking Statements and Non-GAAP Measures

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This presentation contains forward-looking statements within the meaning of federal securities laws, including, among others, any statements about our expectations, plans, intentions, strategies, or prospects. We generally use the words "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "assumes," "guides," "targets," "forecasts," "sees," "sees," "sees," "sees," "should," "could," "would," "predicts," "potential," "strategy," "future," "opportunity," work toward," "intends," "guidance," "confidence," "positioned," "design," "strive," "continue," "track," "look forward to," "optimistic" and similar expressions to identify forward-looking statements. All statements other than statements of historical or current fact are or may be deemed to be forwardlooking statements. Such statements are based upon the current beliefs, expectations, and assumptions of management and are subject to significant risks, uncertainties, and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements. These risks, uncertainties and changes in circumstances include, but are not limited to: dependence on new product development, technological advances and innovation; shifts in the product category or regional sales mix of our products and services; supply and prices of raw materials and products; pricing pressures from competitors, customers, dental practices and insurance providers; changes in customer demand for our products and services caused by demographic changes or other factors; challenges relating to changes in and compliance with governmental laws and regulations affecting our U.S. and international businesses, including regulations of the U.S. Food and Drug Administration and foreign government regulators, such as more stringent requirements for regulatory clearance of products; competition; the impact of healthcare reform measures; reductions in reimbursement levels by third-party payors; cost containment efforts sponsored by government agencies, legislative bodies, the private sector and healthcare group purchasing organizations, including the volume-based procurement process in China; control of costs and expenses; dependence on a limited number of suppliers for key raw materials and outsourced activities; the ability to obtain and maintain adequate intellectual property protection; breaches or failures of our information technology systems or products, including by cyberattack, unauthorized access or theft; the ability to retain the independent agents and distributors who market our products; our ability to attract, retain and develop the highly skilled employees we need to support our business; the effect of mergers and acquisitions on our relationships with customers, suppliers and lenders and on our operating results and businesses generally; the ability to form and implement alliances; changes in tax obligations arising from tax reform measures, including European Union rules on state aid, or examinations by tax authorities; product liability, intellectual property and commercial litigation losses; changes in general industry and market conditions, including domestic and international growth rates; changes in general domestic and international economic conditions, including inflation and interest rate and currency exchange rate fluctuations; the effects of global pandemics and other adverse public health developments on the global economy, our business and operations and the business and operations of our suppliers and customers, including the deferral of elective procedures and our ability to collect accounts receivable; and the impact of the ongoing financial and political uncertainty on countries in the Euro zone on the ability to collect accounts receivable in affected countries. You are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. Forward-looking statements speak only as of the date they are made, and we expressly disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Non-GAAP Financial Measures

This presentation contains financial measures which have not been calculated in accordance with United States generally accepted accounting principles ("GAAP"), because they are a basis upon which our management assesses our performance. Although we believe these measures may be useful for investors for the same reason, these financial measures should not be considered as an alternative to GAAP financial measures as a measure of our financial condition, performance or liquidity. In addition, these financial measures may not be comparable to similar measures used by other companies. In the **Appendix** to this presentation, we provide further descriptions of these non-GAAP measures and reconciliations of these non-GAAP measures to the most directly comparable GAAP measures.



ZimVie: A Global Dental Leader

Powerful, market-leading portfolio of premium implants, restorative implant solutions, biomaterials solutions, and digital dentistry technologies

Leading with differentiated solutions and continuing to invest in innovation

Focused on driving greater adoption of dental implants through training, education, and digital workflow



Clear Strategy for Value Creation

Reposition as pure-play dental business

- Completed sale of spine business in April 2024
- Paid down \$275M of debt, significantly improving balance sheet health

4

 Reducing corporate overhead, IT and legal costs following sale of spine

Reduce expenses;

improve margin profile

 Optimizing manufacturing operations through automation

business

 Aligning global manufacturing footprint to align with areas of competitive advantage

Accelerate implant adoption and growth

- Improving the workflow and economics of implant dentistry via digital products
- Expanding industry leading education and training programs to drive minimally invasive implant dentistry
- Continuing rapid cadence of new production introductions

ZimVie

Key Products & Brands



5

T3[®] PRO Implant

Launched in 2022, the T3® PRO builds on the proven solutions of the T3 Tapered Implant, providing an optimized implant experience for both dentists and patients.



TSX[®] Implant

Launched in 2022, TSX Implants are designed to simplify procedures and optimize practice protocols to deliver peri-implant health, crestal bone maintenance, long-term osseointegration, and prosthetic stability.



Full range of abutments, copings, and analogs Large portfolio of abutments, copings, and analogs in order to facilitate implant procedure success.

Premium implant portfolio catering to both routine and complex cases along with a full range of abutments, copings, and analogs



Biomaterials: Portfolio Overview





Puros[®] Allograft Bone Block

Human-donor sourced bone graft material that allows patients with damaged or inadequate bone quality to be provided with a stable surface for implant application.



Xenograft and Synthetic Bone Grafts Synthetic bone material that can be used to create a suitable surface of implantation.



Puros® Allograft Products

Products used in implant procedures to provide a foundation for the implant and create a desirable aesthetic outcome.



Barrier Membranes

By providing a reliable barrier during the critical phases of wound healing, these membranes help maintain bone growth material.

Biomaterial solutions that are used for soft tissue and bone rehabilitation, helping build sufficient bone necessary for dental implant surgery



Key Products & Brands



RealGUIDE® Software

Software suite that offers precise planning, RealGUIDE® designing, and predictable placement of dental implants and restorations, helping users manage procedural risk more effectively and plan complex cases in a fraction of the time.



7

BellaTek® System

Patient-specific abutments, bars, implant bridges, and hybrid restorations designed to match each patient's tooth anatomy.



Implant Concierge

Virtual treatment planning through Implant Concierge[™] provides outsourced treatment planning services and guided surgery solutions, taking significant workflow out of the dental office.



GenTek[™] System

End-to-end prosthetic offerings designed to support CAD/CAM restorations.

End-to-end solutions ranging from intraoral scanning technology to open architecture CAD/CAM systems, guided surgery solutions, and patient-specific restorations





End-to-End Solutions Save Time and Improve the Clinician and Patient Experience

- Delivering digital workflow enhancements to save clinician time and improve patient satisfaction
- Al facilitated reconstruction procedures require 3 fewer hours of human labor*
- ZimVie Encode Emergence workflow reduces chair time and saves one restorative impression appointment
- Seeing rapid adoption of guided surgery software



implant concierge



ERealGUIDE® UNIVERSAL OPEN SYSTEM Custom Surgical Guide Kits



9 *Internal data

Financial Profile & Outlook



			Drivers of Progress
	Q3 2024*	FY 2024	Best-in-class portfolio and commitment to ongoing innovation
Net Sales	\$103.2M	\$450M-\$455M	Expanding portfolio adoption
Adjusted EBITDA	\$13.1M ⁽¹⁾	\$60M-\$62M ⁽²⁾	within large, underserved dental markets
Adjusted EPS	\$0.12 ⁽¹⁾	\$0.57-\$0.62 ⁽²⁾	Reducing expense profile to improve margins

Continuing to transfer value to shareholders by reducing gross debt by \$290M year-to-date

*Reflects 3Q 2024 continuing operations results. (1) This is a non-GAAP financial measure. Refer to th (2) This is a forward looking non-GAAP financial meas identifies the information that is unavailable witho

able GAAP financial measure is not available without unreason I-Looking Non-GAAP Financial Meas n to the most directly compa



Committed to Executing Strategic Transformation



11

Recent Accomplishments


- Transformed to pure-play dental business
 - Paid down \$275M of debt
- Launched RealGUIDE[®] software update
 - Introduced GenTek Restorative Components (U.S.)


Current Priorities

- Commercialize new product introductions across major geographies
- Drive digital workflow adoption to expand implant adoption
- Address and reduce stranded costs
- Optimize manufacturing & supply chain capabilities
- Position the business for sustainable growth

Market Expansion Opportunities

- Innovate digital workflow to drive efficiency and outcomes for the most complex implant procedures
- Expand geographically with direct representation
- Continue to invest in training and education to drive adoption





Note on Non-GAAP Financial Measures



✓ ZimVie

This presentation includes non-GAAP financial measures that differ from financial measures calculated in accordance with U.S. generally accepted accounting principles ("GAAP"). These non-GAAP financial measures may not be comparable to similar measures reported by other companies and should be considered in addition to, and not as a substitute for, or superior to, other measures prepared in accordance with GAAP.

Adjusted EBITDA is a non-GAAP financial measure provided in this presentation for certain periods and is calculated by excluding certain items from net loss from Continuing Operations on a GAAP basis, as detailed in the reconciliations presented later in this presentation. Adjusted EBITDA margin is Adjusted EBITDA divided by third party net sales from Continuing Operations for the applicable period.

Adjusted diluted earnings (loss) per share is a non-GAAP financial measure provided in this presentation for certain periods and is calculated by excluding the effects of certain items from diluted earnings (loss) per share on a GAAP basis, as detailed in the reconciliations presented later in this presentation.

Reconciliations of these non-GAAP measures to the most directly comparable GAAP financial measures are included in this presentation.

Management uses non-GAAP financial measures internally to evaluate the performance of the business. Additionally, management believes these non-GAAP measures provide meaningful incremental information to investors to consider when evaluating the performance of the company. Management believes these measures offer the ability to make period-to-period comparisons that are not impacted by certain items that can cause dramatic changes in reported income but that do not impact the fundamentals of our operations. The non-GAAP measures enable the evaluation of operating results and trend analysis by allowing a reader to better identify operating trends that may otherwise be masked or distorted by these types of items that are excluded from the non-GAAP measures.

Forward-Looking Non-GAAP Financial Measures

This presentation also includes certain forward-looking non-GAAP financial measures for the year ending December 31, 2024. We calculate forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. We have not provided quantitative reconciliations of these forward-looking non-GAAP financial measures to the most directly comparable forward-looking GAAP financial measures because the excluded items are not available on a prospective basis without unreasonable efforts. For example, the timing of certain transactions is difficult to predict because management's plans may change. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. It is probable that these forward-looking non-GAAP financial measures may be materially different from the corresponding GAAP financial measures.

Reconciliation of Adjusted EBITDA Continuing Operations (\$ in thousands)

2024		For the Nine Months Ended September 30,				
2024	2023	2024	2023			
-	50		100			
\$ 103,222	\$ 105,311	\$ 338,228	\$ 344,131			
			236			
\$ 103,222	\$ 105,311	\$ 338,228	\$ 344,367			
\$ (3,048)	\$ (10,182)	\$ (24,162)	\$ (32,485)			
2,361	4,984	9,828	15,258			
(688)	325	6,161	1,555			
8,490	8,415	25,383	26,057			
7,115	3,542	17,210	10,385			
3,323	4,741	11,761	14,159			
687	1,391	3,664	3,929			
1,276	1,936	6,934	4,647			
-	-	-	(5)			
406	295	1,118	2,227			
287	293	860	864			
\$ 13,094	\$ 12,198	\$ 41,547	\$ 36,206			
-3.0%	-9.7%	-7.1%	-9.4%			
12.7%	11.6%	12.3%	10.5%			
	\$ 103,222 \$ (3,048) 2,361 (688) 8,490 7,115 3,323 687 1,276 - 406 287 \$ 13,094 -3.0%	\$ 103,222 \$ 105,311 \$ 103,222 \$ 105,311 \$ (3,048) \$ (10,182) 2,361 4,984 (688) 325 8,490 8,415 7,115 3,542 3,323 4,741 687 1,391 1,276 1,936 406 295 287 293 \$ 13,094 \$ 12,198 -3.0% -9.7%	\$ 103,222 \$ 105,311 \$ 338,228 \$ 103,222 \$ 105,311 \$ 338,228 \$ 103,222 \$ 105,311 \$ 338,228 \$ (3,048) \$ (10,182) \$ (24,162) \$ 2,361 4,984 9,828 (668) 325 6,161 8,490 8,415 25,383 7,115 3,542 17,210 3,323 4,741 11,761 687 1,391 3,664 1,276 1,936 6,934 406 295 1,118 287 293 860 \$ 13,094 \$ 12,198 \$ 41,547 -3.0% -9.7% -7.1%			

[1] Restructuring activities to better position our organization for future success based on the current business environment and sale of the spine business.
[2] Acquisition, integration, divestiture and related expenses for the three and nine months ended September 30, 2024 include professional services fees (51.9 million and \$5.8 million, respectively) and stranded costs (50.4 million and \$0.9 million, respectively) and transfer docts (50.4 million and \$0.9 million, respectively) inspine segment, partially offset by far value adjustment benefit of the selfer note related to the sale of the spine segment, partially offset by far value adjustment benefit of the selfer note 30, 2023 include professional services fees (51.9 million and \$0.7 million, respectively), inspin and related expenses for the three and nine months ended September 30, 2023 include professional services fees (51.6 million and \$0.7 million, respectively), instanting costs related to the separation from our former parent (\$0.3 million and \$0.7 million, respectively), incruined to prepare for and complete the separation form our former parent (\$0.3 million and \$0.5 million, [2] Expenses incrured for initial compliance with the European Union ("EUT) Medical Device Regulation ("MDR?) for previous/us/paproved products.
[4] Inventory write-dfs resulting from restructuring activities and property, plant, and equipment step-up amotization from prior acquisitions.
[5] Net Loss Margin is calculated as Net Loss divided by third party net sales for the applicable period.
[6] Adjusted EBITDA Margin is Adjusted EBITDA divided by third party net sales for the applicable period.

ZimVie

Reconciliation of Adjusted Net (Loss) Income and Adjusted EPS Continuing Operations (in thousands, except per share data)

	For the Three Months Ended September 30, 2024										2	
Reported	Net Sales		Cost of products sold, excluding intangible asset amortization		Operating expenses, excluding cost of products sold		Operating (Loss) Income		Net (Loss) Income		Diluted EPS	
	\$	103,222	\$	(35,820)	\$	(72,239)	\$	(4,837)	\$	(3,048)	\$	(0.11)
Restructuring and other cost reduction initiatives [1]						687		687		687		0.02
Acquisition, integration, divestiture and related [2]		-		-		1,276		1,276		1,276		0.05
European union medical device regulation [3]		-				406		406		406		0.01
Other charges [4]		-		287		-		287		287		0.01
Intangible asset amortization		-		-		6,037		6,037		6,037		0.22
Share-based compensation modification [5]		-		-		(521)		(521)		(521)		(0.02)
Tax effect of above adjustments & other ^[6]		5 <u>0</u>		2				82		(1,841)		(0.06)
Adjusted	\$	103,222	5	\$ (35,533)	\$	(64,354)	\$	3,335	\$	3,283	\$	0.12

 Restructuring activities to better position the organization and the expenses incurred were primarily related to severance and professional fees.
 Restructuring activities to better position the organization and the expenses incurred were primarily related to severance and professional services fees (\$1.9 million) an segment, particular primary ratio adjustment benefit of the seller note related to the said of the spine segment (\$1.2 million).
 Expenses incurred for initial complance with the EU MDR for previously-approved products.
 Inventory write-offs resulting form restructuring activities and property, plant, and equipment step-up amortization from prior acquisitions.
 Stel Impact to share-based compensation expense of converting outstanding restricted stock units with performance-based metrics based on the consolidate RSUs following the saie of the spine segment.
 Reflects the xelfect of the adjustments from reported to adjusted, as well as an adjustment for management's expectation of ZimVie's statutory tav rate has lidated results of the spine and dental segments into time-based amooni yet-ann hatsuihe hne

ZimVie

in) related to sale of the spine